These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11219973)

  • 21. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
    Diasio RB
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):51-6. PubMed ID: 9556784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
    Yasumatsu R; Nakashima T; Uryu H; Masuda M; Hirakawa N; Shiratsuchi H; Tomita K; Fukushima M; Komune S
    Oral Oncol; 2009 Feb; 45(2):141-7. PubMed ID: 18620897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
    Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
    Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.
    Terashima M; Irinoda T; Fujiwara H; Nakaya T; Takagane A; Abe K; Yonezawa H; Oyama K; Inaba T; Saito K; Takechi T; Fukushima M
    Anticancer Res; 2002; 22(2A):761-8. PubMed ID: 12014648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Inoue K; Takao M; Watanabe F; Tarukawa T; Shimamoto A; Kaneda M; Sakai T; Fukushima M; Shimpo H; Yada I
    Lung Cancer; 2005 Jul; 49(1):47-54. PubMed ID: 15949589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
    Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
    Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
    Lee A; Ezzeldin H; Fourie J; Diasio R
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats.
    Tateishi T; Watanabe M; Nakura H; Tanaka M; Kumai T; Sakata SF; Tamaki N; Ogura K; Nishiyama T; Watabe T; Kobayashi S
    Drug Metab Dispos; 1999 Jun; 27(6):651-4. PubMed ID: 10348793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
    Kakimoto M; Uetake H; Osanai T; Shirota Y; Takagi Y; Takeshita E; Toriya Y; Danenberg K; Danenberg PV; Sugihara K
    Cancer Lett; 2005 Jun; 223(1):103-11. PubMed ID: 15890242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients.
    van Kuilenburg AB; Maring JG
    Pharmacogenomics; 2013 May; 14(7):799-811. PubMed ID: 23651027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
    Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
    Milano G; McLeod HL
    Eur J Cancer; 2000 Jan; 36(1):37-42. PubMed ID: 10741292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
    Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
    Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.
    Ueda M; Kitaura K; Kusada O; Mochizuki Y; Yamada N; Terai Y; Kumagai K; Ueki K; Ueki M
    Jpn J Cancer Res; 2000 Nov; 91(11):1185-91. PubMed ID: 11092985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of 5-fluorouracil by 5-ethyl-2'-deoxyuridine on cell lines expressing different dihydropyrimidine dehydrogenase activities.
    Katona C; Tímár F; Jeney A; Fischel JL; Milano G; Pandi E; Kralovánszky J
    Anticancer Drugs; 1999 Jul; 10(6):561-7. PubMed ID: 10885904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.